Alirocumab safe in patients with diabetes mellitus PROFICIO analysis shows consistent LDL lowering with evolocumab International Atherosclerosis Society and FH Foundation join forces to improve FH management ESC 2018: FOURIER analysis: Greater benefit with evolocumab in metabolic syndrome patients ESC 2018: FOURIER: Evolocumab shows similar benefit in men, women and the elderly ESC 2018: Real-world data vindicate ESC/EAS guidance for PCSK9 inhibitors Two more analyses show efficacy of alirocumab in diabetes OSLER: sustained benefit with evolocumab in statin intolerant patients

Latest News Updates

Home Education & Resources

Education & Resources

Slides

Inclisiran and the ORION clinical development programme

Inclisiran and the ORION clinical development programme

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

How do we recognize FH in clinical practice?

How do we recognize FH in clinical practice?

PCSK9 Inhibitors: A View of Clinical Studies

PCSK9 Inhibitors: A View of Clinical Studies

FH in children and adolescents

FH in children and adolescents View all slides »

Videos

Play

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

Play

FOURIER update: new impetus for guideline groups to reconsider LDL targets

FOURIER update: new impetus for guideline groups to reconsider LDL targets

Play

Is lowering lipoprotein(a) beneficial when LDL-C is very low?

Is lowering lipoprotein(a) beneficial when LDL-C is very low?

Play

How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

View all videos »

Events

European Society of Cardiology Congress
Event start date: 25 Aug 2018
Munich, Germany

14th Asian Interventional Cardiovascular Therapeutics Congress 2018 (AICT 2018)
Event start date: 7 Sep 2018
Wan Chai, Hong Kong

73rd Brazilian Congress Of Cardiology 2018 (SBC 2018)
Event start date: 14 Sep 2018
Brasília, Brazil

View all events »

Trials

View all trials »

Links

View all links »

Guidelines & Consensus Guidance

View all guidelines »

Archived articles

View the archive »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.

Educational Partners and Supporters

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

The Medicines Company

Sanofi Regeneron

© Copyright 2018 PCSK9 Forum. All rights reserved